Patent 11919952 was granted and assigned to Yuhan on March, 2024 by the United States Patent and Trademark Office.
There is disclosed anti-PD-L1 IgG class antibodies that have an improved ability to be manufactured at higher yields. More specifically, there is disclosed human antibodies that bind PD-L1, PD-L1-binding fragments that can be manufactured at higher yields.